Chapter 12
Thrombogenesis and Thrombolysis
Donald Silver,
Leila Mureebe,
Thomas A. Shuster,
Donald Silver
Search for more papers by this authorLeila Mureebe
Search for more papers by this authorThomas A. Shuster
Search for more papers by this authorDonald Silver,
Leila Mureebe,
Thomas A. Shuster,
Donald Silver
Search for more papers by this authorLeila Mureebe
Search for more papers by this authorThomas A. Shuster
Search for more papers by this authorBook Editor(s):Enrico Ascher,
L. H. Hollier,
D. Eugene Strandness,
Jonathan B. Towne,
Keith Calligaro,
K. Craig Kent,
Gregory L. Moneta,
William H. Pearce,
John J. Ricotta,
Henry Haimovici,
Enrico Ascher
Search for more papers by this authorL. H. Hollier
Search for more papers by this authorD. Eugene Strandness
Search for more papers by this authorJonathan B. Towne
Search for more papers by this authorKeith Calligaro
Search for more papers by this authorK. Craig Kent
Search for more papers by this authorGregory L. Moneta
Search for more papers by this authorWilliam H. Pearce
Search for more papers by this authorJohn J. Ricotta
Search for more papers by this authorHenry Haimovici
Search for more papers by this authorFirst published: 01 January 2004
Summary
This chapter contains section titled:
-
Coagulation
-
Anticoagulation
-
Thrombolysis
-
Definitions
-
EpidemiologyæPrevalence and Mortality
References
- Vanhoutte PM. Platelets, endothelium and blood vessel wall. Experientia 1988; 44 (2): 105–109.
- Ruggeri ZM, Dent JA, Saldivar E. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood 1999; 94: 172–178.
- George JN. Platelets. Lancet 2000; 355: 1531–1539.
- Bennett JS. Novel platelet inhibitors. Annu Rev Med 2001; 52: 161–184.
- George JN, Raskob GE, Shah SR, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Int Med 1998; 129 (11): 886–890.
- Mammen EF. Stickey platelet syndrome. Semin Thromb Hemost 1999; 25: 361–365.
- Patrono C. Aspirin as an antiplatelet drug. N Eng J Med 1994; 330: 1287–1294.
- Gachet C. Platelet activation by ADP: the role of ADP antagonists. Ann Med 2000; 1 (Suppl 1): 15–20.
- Ikeda Y. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor. Thromb Hemost 1998; 82: 435–438.
- Tanaka T, Ishikawa T, et al. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology 1988; 36: 313–320.
- Kubota Y, Kichikawa K, et al. Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study. Investig Radiology 1995; 30: 532–537.
- Sudo T, Tachibana K, et al. Potent effects of novel antiplatelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmac 2000; 59: 347–356.
- Tani T, Uehara K, et al. Cilostazol, a selective type III phosphodiesterase inhibitor, decreased triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats. Atherosclerosis 2000; 152: 299–305.
- Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? Circulation 1999; 100: 437–444.
- Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258–264.
- Bajaj SP, Joist JH. New insights into how blood clots: implications for the use of APTT and PT as coagulation screening tests and in monitoring of anticoagulant therapy. Semin Thromb Hemosta 1999; 25: 407–418.
- Broze GJ. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46: 103–112.
- Hedner U, Erhardtsen E. Future possibilities in the regulation of the extrinsic pathway: rFVIIa and TFPI. Ann Med 2000; 32 (Suppl 1): 68–72.
- Minnema MC, Ten Cate H, Hack CE. The role of factor XI in coagulation: a matter of revision. Semin Thromb Hemosta 1999; 25: 419–428.
- Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803–813.
- Wesselschmidt R, Likert K, et al. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul Fibrinoly 1993; 4: 661–669.
- Wu KK, Matijevic-Aleksic N. Thrombomodulin: a linker of coagulation and fibrinolysis and predictor of risk of arterial thrombosis. Ann Med 2000; 32 (Suppl 1): 73–77.
- Baker WF Jr, Bick RL. Treatment of hereditary and acquired thrombophilic disorders. Semin Thromb Hemost 1999; 25: 387–406.
- Eldrup-Jorgensen J, Flanigan DP, et al. Hypercoagulable states and lower limb ischemia in young adults. J Vasc Surg 1989; 9: 334–341.
- Donaldson MC, Weinberg DS, et al. Screening for hypercoagulable states in vascular surgical practice: a preliminary study. [see comments] J Vasc Surg 1990; 11: 825–831.
- Kearon C, Crowther M, Hirsh J. Management of patients with hereditary hypercoagulable disorders. Ann Rev Med 2000; 51: 169–185.
- Rosenberg RD. Actions and interactions of antithrombin and heparin. N Engl J Med 1975; 292: 146–151.
- Tollefsen DM. Laboratory diagnosis of antithrombin and heparin cofactor II deficiency. Semin Thrombo Hemosta 1990; 16 (2): 162–168.
- Bick RL, Ucar K. Hypercoagulability and thrombosis. Hematol Oncol Clin North Am 1992; 6: 1421–1431.
- Comp PC. Hereditary disorders predisposing to thrombosis. Prog Hemost Thromb 1986; 8: 71–102.
- Ahn SS, Kalunian K, et al. Postoperative thrombotic complications in patients with lupus anticoagulant: increased risk after vascular procedures. J Vasc Surg 1988; 7: 749–756.
- Gradman WS, Daniel J, et al. Homocysteine-associated acute mesenteric artery occlusion treated with thrombectomy and bowel resection. Ann Vasc Surg 2001; 15: 247–250.
- Sarkar PK, Lambert LA. Aetiology and treatment of hyperhomocysteinanemia causing ischaemic stroke. Int J Clin Pract 2001; 55: 262–268.
- Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983; 62: 14–31.
-
Rickles FR,
Edwards RL,
et al.
Abnormalities of blood coagulation in patients with cancer. Fibrinopeptide a generation and tumor growth.
Cancer
1983;
51
(2):
301–307.
10.1002/1097-0142(19830115)51:2<301::AID-CNCR2820510223>3.0.CO;2-7 CAS PubMed Web of Science® Google Scholar
- Stadel BV. Oral contraceptives and cardiovascular disease (first of two parts). N Engl J Med 1981; 305: 612–618.
- Vandenbroucke JP, Rosing J, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344: 1527–1535.
- Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabet Complicat 2001; 15 (1): 44–54.
- Tuut M, Hense HW. Smoking, other risk factors and fibrinogen levels. Evidence of effect modification. Ann Epidemiol 2001; 11: 232–238.
- Hioki H, Aoki N, et al. Acute effects of cigarette smoking on platelet-dependent thrombin generation. Eur Heart J 2001; 22: 56–61.
- Matetzky S, Tani S, et al. Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity. Circulation 2000; 102 (6): 602–604.
- McGill HC Jr. The cardiovascular pathology of smoking. Am Heart J 1988; 115 (1 Pt 2): 250–257.
- Laster J, Cikrit D, et al. The heparin-induced thrombocytopenia syndrome: an update. Surgery 1987; 102: 763–770.
- Schafer AI. The hypercoagulable states. Ann Int Med 1985; 102: 814–828.
- Lewis BE, Wallis DE, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 1838–1843.
- Mudaliar JM, Liem TK, et al. Lepirudin is a safe and effective anticoagulant for patients with heparin-associated antiplatelet antibodies. J Vasc Surg 2001; 34 (1): 17–20.
- Forfar JC. A 7-year analysis of haemorrhage in patients on long-term anticoagulant treatment. Br Heart J 1979; 42: 128–132.
- Levine MN, Raskob G, et al. Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119 (1 Suppl): 108–121S.
- Wong PC, Crain EJ, et al. Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis. J Pharmacol Exp Ther 2000; 295: 212–218.
- Lynch JJ, Sitko GR, et al. Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model. Thromb Haemost 1995; 74: 640–645.
- Weitz JI, Hirsh J. New anticoagulant drugs. Chest 2001; 119 (1 Suppl); 95S–107S.
- Turpie AG, Gallus AS, Hoek JA. Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001; 344: 619–625.
- Duckert F. Thrombolytic therapy. Semin Thromb Hemost 1984; 10: 87–103.
- Walker ID, Davidson JF, et al. Acylated streptokinase-plasminogen complex in patients with acute myocardial infarction. Thromb Haemost 1984; 51: 204–206.
- Verstraete M. Third generation thrombolytic agents. Am J Med 2000; 109: 52–58.
- Johnson AJ, McCarty WR. The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase. J Clin Invest 1959; 38: 1627–1643.
- Anonymous. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity: STITLE trial. Ann Surg 1994; 220: 251–268.
- Ouriel K, Veith FJ, Sasahara AA. Thrombosis or peripheral arterial surgery (TOPAS): Phase I results. J Vasc Surg 1996; 23: 64–75.
- Valji K. Evolving strategies for thrombolytic therapy of peripheral vascular occlusions. J Vasc Intervent Radiol 2000; 11: 411–420.
- Vorchheimer DA. Current state of thrombolytic therapy. Curr Cardiol Rep 1999; 1: 212–220.
- Ouriel K, Katzen B, et al. Reteplase in the treatment of peripheral arterial and venous occlusions: a pilot study. J Vasc Interven Radiol 2000; 11: 849–854.
- Davidian MM, Powell A, et al. Initial results of reteplase in the treatment of acute lower extremity arterial occlusions. J Vasc Interven Radiol 2000; 11: 289–294.
- Goldhaber SZ. Thrombolytic therapy for pulmonary embolism. Semin Vasc Surg 1992; 5: 69–75.
- Comerota AJ, Aldridge SC. Thrombolytic therapy for deep vein thrombosis. Semin Vasc Surg 1992; 5: 76–81.
- Berridge DC, Gregson RH, et al. Randomized trial of intraarterial recombinant tissue plasminogen activator, intravenous recombinant tissue plasminogen activator and intraarterial streptokinase in peripheral arterial thrombolysis. Br J Surg 1991; 78: 988–995.
- Machleder HI. Evaluation of a new treatment strategy for Paget-Schroetter syndrome: spontaneous thrombosis of the axillary-subclavian vein. J Vasc Surg 1993; 17: 305–317.
